Abstract
The pharmacology of BCNU, an active antitumor agent in animal and man, was studied with the use of the C14‐labeled drug. Radioactivity was excreted slowly in man and monkeys and rapidly in mice. Urinary excretion accounted for the maior portion of the isotope although as much as ten per cent was excreted as CO,. The compound is rapidly degraded and promptly after administration no intact drug is demonstrable, although plasma levels of the isotope are prolonged by protein binding of a portion of the drug. Part of the drug may be recirculated in the bile and partially accounts for the prolonged plasma levels. The drug is stable in an acid milieu and well absorbed orally. Its high lipid solubility allows it to readily cross the blood‐brain barrier. The active moiety of this agent is still unknown. The contrast of the short biologic half‐life of intact BCNU to the delayed clinical toxicity and prolonged plasma levels of carbon‐14 is interesting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
